MESO Mesoblast Limited

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...

With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies, where the original builders still call key shots, can look appealing when capital is more expensive and decisions carry extra weight. This article highlights three such stocks from our founder focused screener. These three founder led Australian stocks are...

Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...

Global bond yields are climbing, and central banks are tightening policy to keep inflation in check. That raises the bar for every listed company. Founder led Australian businesses can be different because leaders often have more of their own wealth and reputation on the line when conditions get tougher. This article highlights three stocks from our founder focused screener that explore how owner minded leadership may influence long term value creation. These three founder led stocks are just...

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9

Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become interesting. When management has significant skin in the game, their long-term outlook aligns more closely with yours. This article highlights three stocks from that screener that fit this theme today. The three stocks below are just a small sample of the...

Global debt markets are back in focus as the US 10 year yield hovers around the mid 4% range ahead of Jackson Hole. Higher yields can punish weaker balance sheets, yet they often highlight companies that still commit their own capital. This is where fast growing stocks with high insider ownership come in. This article explores three such stocks that align with this theme today. The stocks highlighted below are just a sample, with the full screen surfacing 102 more companies where insiders...

With central banks in several regions still pricing in tighter policy as they watch inflation and growth data, plenty of investors are looking down the market cap spectrum for ideas that do not rely on cheap money to work. That is where the Financially Fit Penny Stocks screener comes in. It filters for lower priced stocks with healthier balance sheets. This article highlights three of the most interesting options from that list. The three stocks below are just a starting sample from this...

Energy remains a wild card for inflation, with oil prices and broader energy costs still shaping central bank thinking. When policy can shift quickly, many investors look for something more anchored than quarterly guidance. Founder led companies often fit that bill, with leaders whose own legacies are on the line. This article highlights three founder led stocks from our screener that show how that mindset can matter. The three founder led stocks below are just a starting sample, and the full...

Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of

Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate debate, because markets often pay close attention to future earnings strength and financial resilience. This article highlights three stocks from the screener that meet both tests and explains what sets each apart. The three stocks highlighted below are just...

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Mesoblast Limited (NASDAQ:MESO) shares rose 9. 5% on Monday after the biotechnology company completed patient treatment in a pivotal Phase 3 study evaluating rexlemestrocel-L for chronic low back pain linked to degenerative disc disease.

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively tr